Background Nivolumab (NIV) is a monoclonal antibody for patients with pre-treated advanced nonsquamous non–small-cell lung cancer (NSCLC). It is necessary to evaluate the cost effectiveness of NIV versus docetaxel (DOC), taking into consideration the expression of programmed death ligand 1 (PD-L1).
Purpose Cost-effectiveness analysis from the payer’s perspective of NIV versus DOC in patient with nonsquamus NSCLC by expression of PD-L1 test (subgroups:<10% vs.≥10%).
Material and methods Efficacy data were obtained from the CheckMate-057 trial to model the incremental cost-effectiveness ratio (ICER) of NIV versus DOC:
Difference of overall survival (OS) between NIV vs. DOC: PD-L1 expression ≥10%: 0.9 life years gained (LYG) and PDL1 expression <10%: −0.03 LYG.
Drug costs were estimated considering manufacturing costs plus VAT (4%). NIV: mg/m2; DOC: mg/m2. An adult patient was considered (weight=70 kg; body surface: 1.7 m2) (total doses per administration: NIV: 210 mg; DOC: 127.5 mg). Total treatment costs were estimated with the median of the number of administrations received (NIV: six administrations; DOC: four administrations). Other costs were not considered.
Time horizon considered: 1 year.
Two different one-way sensitivity analyses were performed to test the robustness of the model.
Scenario 1: Difference in OS variation was considered.
Variations of ±20% OS were performed:
PDL1 expression ≥10%. Interval considered: 0.792 LYG – 1.18 LYG.
PDL1 expression <10%. Interval considered: −0.036 LYG – −0.024 LYG.
Scenario 2: Cost mg variation was considered. Variations of ±25% were performed.
Interval considered: €17.14/mg – €10.28/mg.
Results Treatment total costs were: NIV: €17,274.60 and DOC: 1167.92€.
The ICER observed in the subgroup with PD-L1 expression ≥10% was €16,269.37/LYG. Otherwise, the ICER estimated in patients with PDL1 expression <10% was €536,889.33/LYG.
No relevant differences in ICER were observed after both one-way sensitivity analyses were performed (OS variation and cost mg variation).
Conclusion NIV vs. DOC is cost effective in patients with non-squamous NSCLC with PD-L1 expression ≥10%, although ICER is high.
NIV vs. DOC is not cost effective in patients with non-squamous NSCLC with PD-L1 expression <10%.
Reference and/or Acknowledgements 1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med2015;373:1627–39.
No conflict of interest
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.